Chronic Obstructive Pulmonary Disease Copd Epidemiology Forecast Insight

DelveInsight’s ‘Chronic Obstructive Pulmonary Disease (COPD)—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Chronic Obstructive Pulmonary Disease (COPD), historical and forecasted epidemiology as well as the Chronic Obstructive Pulmonary Disease (COPD) trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Chronic Obstructive Pulmonary Disease (COPD) Disease Understanding

Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.

 

The most common respiratory symptoms include dyspnea, cough, and/or sputum production; these symptoms may be under-reported by patients. The main risk factor for COPD is tobacco smoking, but other environmental exposures such as biomass fuel exposure and air pollution may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development, and accelerated aging. COPD may be punctuated by periods of acute worsening of respiratory symptoms, called exacerbations. In most patients, COPD is associated with significant concomitant chronic diseases, which increase its morbidity and mortality. COPD is a long-lasting lung disease where the small airways in the lungs are damaged, making it harder for air to get in and out.

Continued in the report…..

Chronic Obstructive Pulmonary Disease (COPD) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Gender-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation, and Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Chronic Obstructive Pulmonary Disease (COPD) Detailed Epidemiology Segmentation

  • The total diagnosed prevalent population of Chronic Obstructive Pulmonary Disease (COPD) in seven major markets was found to be 31,730,590 in 2020 and is anticipated to increase in 2030.
  • The estimates suggest a higher diagnosed prevalence of COPD in the United States with 17,455,605 diagnosed cases in 2020, which might increase in 2030.
  • The majority of cases of Chronic Obstructive Pulmonary Disease (COPD) are female as compared to male, in the US. But in EU-5 and Japan the diagnosed cases of males represents majority of the cases.
  • In the epidemiology model of Chronic Obstructive Pulmonary Disease (COPD), there are multiple age groups referred ranging from 18–44 years, 45–54 years, 55–64 years, 64–74 years, and 75+ years, for COPD in the US. The highest was 4,601,558 in the age group 55–64 years, in 2020.
  • In 2020, the US had 2,967,453, 8,727,802, 4,538,457 and 1,221,892 cases of GOLD 1, GOLD 2, GOLD 3, and GOLD 4.

Scope of the Report

  • The report covers the descriptive overview of Chronic Obstructive Pulmonary Disease (COPD), explaining its causes, symptoms, pathophysiology, and genetic basis.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden and highlights the unmet needs of Chronic Obstructive Pulmonary Disease (COPD).
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM Total Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Gender-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD), Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation, and Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History.

Report Highlights

  • 10-Year Forecast of Chronic Obstructive Pulmonary Disease (COPD)  
  • 7MM Coverage
  • Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD)
  • Gender-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD)
  • Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease (COPD)
  • Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation
  • Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History

Key Questions Answered

  • What are the disease risk, and burden of Chronic Obstructive Pulmonary Disease (COPD)?
  • What is the historical Chronic Obstructive Pulmonary Disease (COPD) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Chronic Obstructive Pulmonary Disease (COPD) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Chronic Obstructive Pulmonary Disease (COPD)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Chronic Obstructive Pulmonary Disease (COPD) during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Chronic Obstructive Pulmonary Disease (COPD) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Chronic Obstructive Pulmonary Disease (COPD) epidemiology forecast.
  • The Chronic Obstructive Pulmonary Disease (COPD) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Chronic Obstructive Pulmonary Disease (COPD) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Executive Summary of Chronic Obstructive Pulmonary Disease (COPD)

4. Key Events

5. Disease Background and Overview

5.1. Introduction

5.2. Factors That Influence Disease Development and Progression

5.3. Symptoms

5.4. Types

5.5. Classification

5.6. Stages

5.7. Pathology, Pathogenesis, and Pathophysiology

5.8. Diagnosis

5.8.1. Differential Diagnosis

5.8.2. Diagnostic Algorithm

5.8.3. Diagnostic Guidelines

5.8.3.1. Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

5.8.3.2. Chronic Obstructive Pulmonary Disease: Diagnosis and Management

5.8.3.3. Guidelines for the Diagnosis and Treatment of COPD (Chronic Obstructive Pulmonary Disease) 3rd edition

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.3. Assumptions and Rationale: 7MM

6.3.1. US Assumptions and Rationale

6.3.2. EU5 Assumptions and Rationale

6.3.3. JP Assumptions and Rationale

6.4. Total Diagnosed Prevalent Patient Population of Chronic Obstructive Pulmonary Disease in the 7MM

6.5. The United States

6.5.1. Diagnosed Prevalent Cases of COPD in the United States

6.5.2. Gender-specific Diagnosed Prevalent Cases of COPD in the United States

6.5.3. Age-specific Diagnosed Prevalent Cases of COPD in the United States

6.5.4. Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States

6.5.5. Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States

6.6. Europe

6.6.1. Diagnosed Prevalent Cases of COPD in Europe

6.6.2. Gender-specific Diagnosed Prevalent Cases of COPD in Europe

6.6.3. Age-specific Diagnosed Prevalent Cases of COPD in Europe

6.6.4. Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe

6.6.5. Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Europe

6.7. Japan

6.7.1. Diagnosed Prevalent Cases of COPD in Japan

6.7.2. Gender-specific Diagnosed Prevalent Cases of COPD in Japan

6.7.3. Age-specific Diagnosed Prevalent Cases of COPD in Japan

6.7.4. Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan

6.7.5. Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan

7. Appendix

7.1. Bibliography

7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Table

Table 1: Summary of COPD Epidemiology (2018–2030)

Table 2: Key Events

Table 3: COPD Classification According to Symptom and Severity Risk

Table 4: Key Indicators for Considering a Diagnosis for COPD

Table 5: Classification of Airflow Limitation Severity in COPD (Based on Post-bronchodilator FEV1)

Table 6: Differential Diagnosis of COPD

Table 7: Pharmacological Characteristics of Approved Bronchodilators for COPD Treatment

Table 8: Pharmacological Treatment of COPD Based on Phenotypes and Disease Severity (GOLD stage I–IV)

Table 9: Antibiotic Dosing for Treatment of COPD Exacerbations

Table 10: Pharmacologic Options That are not Recommended for COPD

Table 11: Key points

Table 12: Vaccination For Stable COPD

Table 13: Total Diagnosed Prevalent Population of Chronic Obstructive Pulmonary Disease in the 7MM (2018–2030)

Table 14: Diagnosed Prevalent Cases of COPD in the United States (2018–2030)

Table 15: Gender-specific Diagnosed Prevalent Cases of COPD in the United States (2018–2030)

Table 16: Age-specific Diagnosed Prevalent Cases of COPD in the United States (2018–2030)

Table 17: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States (2018–2030)

Table 18: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States (2018–2030)

Table 19: Diagnosed Prevalent Cases of COPD in Europe (2018–2030)

Table 20: Gender-specific Diagnosed Prevalent Cases of COPD in Europe (2018–2030)

Table 21: Age-specific Diagnosed Prevalent Cases of Chronic Obstructive Pulmonary Disease in Europe (2018–2030)

Table 22: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe (2018–2030)

Table 23: COPD Classification Based on Severity of Airflow Limitation in Europe (2018–2030)

Table 24: Diagnosed Prevalent Cases of COPD in Japan (2018–2030)

Table 25: Gender-specific Diagnosed Prevalent Cases of COPD in Japan (2018–2030)

Table 26: Age-specific Diagnosed Prevalent Cases of COPD in Japan (2018–2030)

Table 27: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan (2018–2030)

Table 28: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan (2018–2030)

List of Figures

Figure 1: Etiology, Pathobiology, Pathology of COPD Leading to Airflow Limitation and Clinical Manifestations

Figure 2: Types of COPD – Emphysema and Chronic Bronchitis

Figure 3: Pathways of the Diagnosis of COPD

Figure 4: Spirometry Tracing in Normal Individual Versus Spirometry Tracing Typical of a Patient With Obstructive Disease

Figure 5: ABCD Assessment Tool

Figure 6: Diagnostic Algorithm of the Clinical Phenotypes

Figure 7: Flowchart for the Treatment of Stable Chronic Obstructive Pulmonary Disease (COPD)

Figure 8: Bronchodilator Therapy for Patients With Confirmed, Stable COPD

Figure 9: Algorithm for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Figure 10: Follow-up Pharmacological Treatment

Figure 11: Total Diagnosed Prevalent Patient Population of Chronic Obstructive Pulmonary Disease in the 7MM (2018–2030)

Figure 12: Diagnosed Prevalent Cases of COPD in the United States (2018–2030)

Figure 13: Gender-specific Diagnosed Prevalent Cases of COPD in the United States (2018–2030)

Figure 14: Age-specific Diagnosed Prevalent Cases of COPD in the United States (2018–2030)

Figure 15: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in the United States (2018–2030)

Figure 16: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in the United States (2018–2030)

Figure 17: Diagnosed Prevalent Cases of COPD in Europe (2018–2030)

Figure 18: Gender-specific Diagnosed Prevalent Cases of COPD in Europe (2018–2030)

Figure 19: Age-specific Diagnosed Prevalent Cases of COPD in Europe (2018–2030)

Figure 20: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Europe (2018–2030)

Figure 21: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Europe (2018–2030)

Figure 22: Diagnosed Prevalent Cases of COPD in Japan (2018–2030)

Figure 23: Gender-specific Diagnosed Prevalent Cases of COPD in Japan (2018–2030)

Figure 24: Age-specific Diagnosed Prevalent Cases of COPD in Japan (2018–2030)

Figure 25: Diagnosed Prevalent Cases of COPD Based on Severity of Airflow Limitation in Japan (2018–2030)

Figure 26: Diagnosed Prevalent Cases of COPD Based on Symptoms and Exacerbation History in Japan (2018–2030)

Forward to Friend

Need A Quote